课题基金 / 基金详情

Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study

Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study
在新诊断的转移性胰腺腺癌中使用 FOLFIRINOX 进行多途径胆固醇消耗：可行性和概念验证研究
批准号：
402794
负责人：
Gangloff Anne
金额：
$11.15万
依托单位：
CHU de Qubec
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-03-01 至 2021-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=402794&lang=en
关键词：
Acceptability Of The Regimen Biomarkers (Lipid Profile, Tumoral Ldlr, Npc1l1, Srb1) Cholesterol-Lowering Drugs (Pcsk9 Inh, Statins, Ezetimibe) Clinical Trial (Non-Randomized, Open-Label) Dose-Limiting Toxicities Estimates Of Progression-Free Survival

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
According to the Canadian Cancer Statistics, out of 100 patients diagnosed with pancreatic cancer, only 8 will still be alive 5 years later. Most patients will die within the first year after diagnosis. Given this very poor survival, there is an urgent ne
期刊论文(0)
专著(0)
科研奖励(0)
会议论文